+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07265947

Evaluating Dabogratinib TYRA-300 for Low Grade Upper Tract Urothelial Carcinoma A Phase 2AB Open-Label Multi-center Study

Led by Tyra Biosciences, Inc · Updated on 2026-11-02

285

Participants Needed

36

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Dabogratinib TYRA-300 in a Phase 2AB study involving participants with Low Grade Upper Tract Urothelial Carcinoma LG UTUC. This open-label, multi-center trial aims to assess the safety and effectiveness of Dabogratinib in treating this specific type of urothelial carcinoma, focusing on participants with FGFR3 positive tumors. The study is sponsored by Tyra Biosciences, Inc and includes randomized treatment groups receiving different doses of Dabogratinib. Participants receive Dabogratinib as a self-administered oral tablet daily at either 60mg or 80mg doses. The study includes two treatment cohorts and is designed to monitor the drugs impact on tumor response, including complete response rates and duration of response. The trial allows evaluation over a period of up to 36 months for response duration and up to 2 years for safety, renal preservation, and tumor resectability changes. During the trial, participants undergo assessments to measure tumor response, safety, and tolerability. Marker lesions are identified prior to randomization and monitored throughout. Researchers track outcomes including complete response rates within 6 months, maintenance of response at 12 and 24 months, and kidney function preservation. Laboratory tests, imaging, and clinical evaluations are performed regularly. The total participation time can extend up to several years to capture long-term effects and safety data.

CONDITIONS

Brief Title

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Research Team

L

Lara Balick

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here